In July 2023, Enzyvant, now Sumitomo Pharma America, a subsidiary of Sumitomo Pharma, announced an update on their Phase 2 ELEVATE 2 study of Rodatristat Ethyl for PAH. The Phase 2b study failed to lower pulmonary vascular resistance, as measured by right heart catheterization, at Week 24. Sumitomo undertook a very rigorous evaluation of Rodatristat Ethyl in PAH. This … [Read more...]
Why Abortion Matters to PAH Patients
Across America a woman’s right to terminate an unwanted pregnancy is under threat. Without diving into politics or religion I want to impress on the PAH community why this may spell disaster for our PAH patients. The Supreme Court is on the verge of reversing half a century of legal precedent that has protected a woman’s right to choose. At the same time, several states have … [Read more...]
Sotatercept for Pulmonary Arterial Hypertension
For the past 30 years, all our pulmonary arterial hypertension medications were described as vasodilators: First prostanoids (epoprostenol), then endothelin receptor antagonists (bosentan, ambrisentan, macitentan) and PDE5 inhibitors (sildenafil and tadalafil). These medications work through different mechanism but all lead to the vasodilation or … [Read more...]
Back in Action
Please forgive the hiatus in posting new content. When I am not caring for pulmonary hypertension and pulmonary fibrosis patients I am also an intensive care unit doctor and have been inundated caring for many thousands of patients with severe COVID. My team and I have cared for well over 8,000 patients with severe COVID during the past two years. Over the past year it has … [Read more...]
5 Tips for PH Patients During Flu & Cold Season
It is that time of year when the flu and cold are being passed around with holiday cookies and cards. Below are 5 helpful tips to help PH patients avoid getting sick. … [Read more...]
